drugset / Trial / NCT01535495
Propranolol for Diabetic Retinopathy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is investigating if the oral beta antagonist propranolol can induce regression of retinal neovascularization associated with proliferative diabetic retinopathy.
Timeline
- Start
- 2012-02
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Propranolol | Small molecule | 120 mg | Oral |